301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC

Irene Scarfo; Laura Lim; Kevin Dang; Marvin Chew; Rakesh Sudhakah; Michelle Nguyen; Suchismita Mohanty; Jeremy Chen; Alma Gomez; Nickolas Attanasio; Amanda Fearon; Ivan Chan; Vibhavari Sail; Thomas J Gardner; Beatriz Millare; James Zhang; Darrian Moskowitz; Vince Thomas; Stanley Zhou; Jenessa Smith; Jennifer McDevitt; Angela Boroughs

doi:10.1136/jitc-2023-SITC2023.0301

Citation Tools

Regular and Young Investigator Award Abstracts

Cellular Therapies

301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Scarfo I, Lim L, Dang K, et al

301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC

Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0301

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password